Research progress and design optimization of CAR‐T therapy for pancreatic ductal adenocarcinoma

Research progress and design optimization of CAR‐T therapy for pancreatic ductal adenocarcinoma

Abstract Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant cancer with limited treatment options. Chimeric antigen receptor T cells (CAR‐T) are genetically engineered T cells that can specifically kill tumor cells without major histocompatibility complex restriction. Encouraging progress...

Full description

Bibliographic Details
Main Authors: Tianjiao Li, Hao Li, Shuo Li, Shuaishuai Xu, Wuhu Zhang, Heli Gao, Huaxiang Xu, Chuntao Wu, Wenquan Wang, Xianjun Yu, Liang Liu
Format: Article
Language:English
Published: Wiley 2019-09-01
Series:Cancer Medicine
Subjects:
CAR‐T
design optimization
immunotherapy
PDAC
Online Access:https://doi.org/10.1002/cam4.2430

Internet

https://doi.org/10.1002/cam4.2430

Similar Items